As of May 27
| +0.37 / +1.97%|
The 7 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 24.00, with a high estimate of 37.00 and a low estimate of 19.00. The median estimate represents a +25.33% increase from the last price of 19.15.
The current consensus among 7 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.